Diss. (sammanfattning) Uppsala : Uppsala universitet, 2005. / Härtill 4 uppsatser.

Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal

Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal.

The serotonergic and cholinergic systems are jointly involved in regulating sleep but this balance is theorized to be disturbed in depressed individuals (Janowsky 1972, Jouvet 1972). One potential cause of disturbed neurotransmission is genetic predisposition. The G(-1019) allele of the 5-HT1A receptor predicts an increased risk for depression compared to the wild-type C(-1019) allele. The goal of this study was to use pharmacological probes in normal controls to model the serotonergic/cholinergic imbalance of depression and its associated abnormalities in sleep structure while controlling for 5-HT1A receptor genotype. Seventeen healthy female participants homozygous for either C (n=11) or G (n=6) alleles, age 18-27 years were tested on four non-consecutive nights. Participants were given galantamine (an anti-acetylcholinesterase), buspirone (a serotonergic agonist), both drugs together, or placebos before sleeping. Buspirone suppressed tonic REM: there was a significant increase in REM latency (p<0.001). Galantamine increased tonic REM sleep, leading to more time spent in stage REM (p<0.001) and shorter REM latency (p<0.01). Galantamine and buspirone given together tended to negate the effects of each other on REM sleep measures but disrupted sleep more than either drug alone, showing lower SE and N3% and increased awakenings, Wake% and N1% (p<0.019). There was no main effect of genotype nor was there a significant multivariate interaction between genotype and drug condition. These findings are partially consistent with the literature about sleep in depression, notably short REM latency, higher percentage of total sleep time spent in REM, and increased sleep fragmentation. The C/G mutation in the 5-HT1A receptor does not appear to cause noticeable differences in the sleep patterns of healthy young females.

The objective of this research was to investigate two important aspects of buccal drug delivery, transport and mucoadhesion. Buspirone was chosen as a model drug for the in vitro buccal transport studies, polyvinyl alcohol and sodium alginate polymer blends were prepared to investigate the mucoadhesive properties through a Lewis acid-base approach and finally, the effect of formulation factors on the force of mucoadhesion, surface energy parameters, release rate and flux was studied. In vitro permeation studies were conducted to investigate the buccal transport pathway of buspirone. Mathematical models were developed to quantify the process of permeation. Permeation enhancement of buspirone across the buccal mucosa was investigated using bile salts (sodium glycocholate and taurodeoxycholate), propylene glycol, propylene. Effect of formulation factors like drug, enhancer, and plasticizer was studied through statistically designed experiments. These experiments aided in characterizing the buccal delivery system. Mathematical models were developed for surface energy parameters, force of mucoadhesion, release rate, and flux. Research conducted in this dissertation focused on two important aspects of transbuccal delivery, drug transport and mucoadhesion by studying a model drug and polymer blends. The results obtained in these investigations can be utilized in the development of other bioadhesive delivery systems with respect to drug transport and mucoadhesion. Polymer blends of polyvinyl alcohol (PVA) and sodium alginate (Alg) were prepared to evaluate their mucoadhesive properties and investigate mucoadhesive mechanism by a Lewis acid-base approach. (Abstract shortened by UMI.)

Tyrimo objektas – kraujo plazma su vaistinių medžiagų mišiniu (buspirono hidrochloridu ir fluoksetino hidrochloridu). Šio tyrimo tikslas – nustatyti tinkamiausias ekstrakcijos sąlygas, reikalingas vaistų mišinio (buspirono ir fluoksetino) išskyrimui iš kraujo plazmos bei pritaikyti efektyviosios skysčių chromatografijos metodiką vaistų mišinio veikliųjų junginių identifikavimui ir kiekio nustatymui. Darbo uždaviniai buvo pritaikyti ir validuoti efektyviosios skysčių chromatografijos metodiką; išskirti buspirono ir fluoksetino vaistų mišinį iš kraujo plazmos skysčių – skysčių (SSE) ir kietafazės ekstrakcijos (KFE) metodais; optimizuoti geriausią ekstrakcijos metodą. Tyrimo metu buvo pritaikyta ESC metodika buspirono ir fluoksetino identifikavimui ir kiekio nustatymui. Atlikta ESC metodikos validacija: įrodytas specifiškumas, rezultatų glaudumas, remiantis koreliacijos koeficientu (R2) įvertintas metodikos teisiškumas, buspirono ir fluoksetino koreliacijos koeficientai atitinkamai lygūs 0,9997 ir 0,9998. Nustatytos aptikimo ribos (buspironui 0,4 µg/ml, fluoksetinui 0,75 µg/ml) ir nustatymo ribos (buspironui 0,75 µg/ml, fluoksetinui 1 µg/ml). Vaistinių medžiagų mišinys išskirtas iš kraujo plazmos SSE ir KFE metodais. Nustatyta, kad KFE yra greitesnis ir tikslesnis metodas lyginant su SSE, todėl KFE pasirinkta tolesniam metodo optimizavimui. Eksperimentai atlikti su 6 organiniais tirpikliais (metanoliu, etanoliu, propanoliu, trichlormetanu, dichlormetanu ir acetonitrilu)... [toliau žr. visą tekstą] / The object of study – human plasma with the mix of two drugs (buspirone hydrochloride and fluoxetine hydrochloride). The aim of this study was to determine extraction conditions for buspirone and fluoxetine isolation from human plasma and to apply high-performance liquid chromatography (HPLC) method for quantitative analysis of the drugs after extraction. The objective was to apply and validate HPLC procedure; to extract buspirone and fluoxetine from human plasma by liquid-liquid extraction (LLE) and solid phase extraction (SPE); to optimize efectiveness extraction method. The HPLC method for identification and quantitative analysis of drugs was optimized. The mobile phase was 0,1 per cent of trifluoroacetic acid and acetonitrile.Validation of the HPLC method was carried out. The specificity, precision, linearity, limits of detection (buspirone 0,4 µg/ml, fluoxetine 0,75 µg/ml) and quantification (buspirone 0,75 µg/ml, fluoxetine 1 µg/ml) were determined. Validate HPLC method was applied for analysis of buspirone and fluoxetine after extraction. Drugs were extracted from human plasma by LLE and SPE methods. The best recovery of analites gave SPE methods. The recoveries of the drugs using six different organic solvents (methanol, propanol, ethanol, trichloromethane, dichloromethane, acetonitrile) were examined. Selected the most appropriate environment (acidify) for methanol and the methanol percentage of the elution solvent (80 per cent). Selected two of the most appropriate... [to full text]

Submitted by Helmut Patrocinio (hell.kenn@gmail.com) on 2017-11-24T01:32:25Z No. of bitstreams: 1 Cl?udio_Queiroz_Disserta??o.pdf: 793741 bytes, checksum: f79a2a4bb52a8be9ba0b57baec9ed09c (MD5) / Approved for entry into archive by Ismael Pereira (ismael@neuro.ufrn.br) on 2017-11-27T16:10:35Z (GMT) No. of bitstreams: 1 Cl?udio_Queiroz_Disserta??o.pdf: 793741 bytes, checksum: f79a2a4bb52a8be9ba0b57baec9ed09c (MD5) / Made available in DSpace on 2017-11-27T16:11:41Z (GMT). No. of bitstreams: 1 Cl?udio_Queiroz_Disserta??o.pdf: 793741 bytes, checksum: f79a2a4bb52a8be9ba0b57baec9ed09c (MD5) Previous issue date: 1999 / Nos ?ltimos dois s?culos, o conhecimento sobre o sistema nervoso central expandiu-se consideravelmente, possibilitando atualmente o tratamento de muitas patologias do sistema nervoso central. Uma dessas patologias, entretanto, a discinesia tardia n?o apresenta nenhum tratamento terap?utico de efic?cia comprovada (Soares, 1997). A discinesia tardia ? uma s?ndrome caracterizada por movimentos involunt?rios repetitivos, normalmente envolvendo a l?ngua, boca e face, ocasionalmente atingindo tamb?m o pesco?o, membros superiores e quadris. Acredita-se ser a discinesia tardia um efeito colateral da exposi??o prolongada aos antipsic?ticos (neurol?pticos). Essa disfun??o motora pode persistir por meses ou anos ap?s a retirada do tratamento com neurol?ptico, podendo at? mesmo ser irrevers?vel (Karniol, 1979; Casey, 1985; Kane, 1995). Nesta tese de Mestrado, procuramos estudar os efeitos comportamentais da administra??o de buspirona sobre modelos animais de discinesia tardia. Os modelos animais utilizados foram: [1] a supersensibilidade dopamin?rgica induzida por um tratamento prolongado com haloperidol e quantificada pela atividade espont?nea de ratos em um campo aberto e [2] pelo comportamento estereotipado induzido pela apomorfina e [3] a quantifica??o dos movimentos orofaciais de ratos ap?s um tratamento repetido com reserpina. O tratamento prolongado com buspirona per se (3.0 mg/kg, i.p., duas vezes ao dia, por 30 dias) n?o resultou em uma supersensibilidade comportamental em nenhum dos dois modelos animais. O tratamento concomitante de buspirona foi capaz de diminuir os sintomas da supersensibilidade dopamin?rgica induzida pelo haloperidol (2.0 mg/kg, i.p., uma vez ao dia, por 30 dias) e quantificada pela atividade geral em campo aberto, mas n?o pelo comportamento estereotipado induzido pela apomorfina. Nos experimentos agudos, apesar de a buspirona per se diminuir tanto a atividade gera em campo aberto como o comportamento estereotipado induzido pela apomorfina, a co-administra??o de buspirona n?o foi capaz de modificar o efeitos agudos do haloperidol sobre esses dois modelos animais. No terceiro modelo, ratos foram tratados com salina ou buspirona (3.0 mg/kg, i.p., duas vezes ao dia) e ve?culo ou reserpina (0.1 mg/kg, s.c., dias intercalados) por 19 dias. No vig?simo dia, os animais foram observados para a quantifica??o de seus movimentos orofaciais: freq??ncia de protrus?o de l?ngua e movimentos mandibulares e dura??o do tremor facial. O tratamento com buspirona per se n?o foi capaz de induzir a movimentos orofaciais. Animais tratados com reserpina apresentaram maior freq??ncia de movimentos orofaciais em rela??o aos animais tratados com salina. A co-administra??o de buspirona foi capaz de atenuar o desenvolvimento da discinesia orofacial induzida pela reserpina. Verificou-se, tamb?m, que os animais tratados cronicamente com buspirona (3.0 mg/kg, i.p., duas vezes ao dia, 30 dias) desenvolvem maior resposta ao comportamento de bocejo induzido pela apomorfina. Assim, com este trabalho observamos que o tratamento prolongado com buspirona foi capaz de atenuar comportamentos dependentes da disponibilidade de dopamina end?gena (atividade geral em campo aberto e movimentos orofaciais induzidos pela reserpina) provavelmente por meio de uma supersensibilidade dos receptores pr?-sin?pticos (sugerida pelo aumento do comportamento de bocejo induzido por apomorfina). Os dados aqui apresentados, juntamente com a literatura cl?nica existente at? o momento, sugerem um poss?vel papel terap?utico da buspirona no tratamento da discinesia tardia. / In the last two centuries, the knowledgement about the central nervous systems increased enormously, making possible the treatment of patients who suffer of all sort of central nervous systems? diseases. One of this diseases is Tardive Dyskinesia, a syndrome characterized by repetitive involuntary movements, usually involving mouth, face and tongue and sometimes limb and trunk musculature. The syndrome is considered to be an adverse effect of prolonged administration of antipsychotic drugs (normally named neuroleptics). It persists for moths after neuroleptic has been discontinued and may be irreversible (Karniol, 1979; Casey, 1985; Kane, 1995). In a recent meta-analysis study, Soares (1997) concluded that there is no efficacious therapeutic interventions for tardive dyskinesia. In this thesis, we studied the behavior effects of buspirone administration on animal models of tardive dyskinesia. These models comprised the [1] dopaminergic supersensitivity induced by long-term haloperidol administration, which is quantified by the spontaneous activity (locomotion and rearing frequency) of rats observed in an open-field or [2] by the apomorphine-induced stereotyped behavior, and [3] the quantification of orofacial dyskinesia in rats repeatedly treated with reserpine. In the first an second models, buspirone per se (3.0 mg/kg, i.p., twice daily, for 30 days) did not produce dopaminergic supersensitivity. When buspirone was given in combination to haloperidol (2.0 mg/kg, i.p., once daily, for 30 days), it decreased the neuroleptic withdrawal symptoms as detected in open-field but not in apomorphine-induced stereotypy. Although single administration of buspirone per se decreased both open-field and apomorphine-induced stereotypy behavior, buspirone single administration did not modify the acute effects of haloperidol on these two behavioral models. In the third model, rats were co-treated with saline or buspirone (3.0 mg/kg, i.p., twice daily) and vehicle or reserpine (0.1 mg/kg, s.c., once every other day) for 19 days. On the day 20, the animals were observed for the quantification of the behavioral parameters of orofacial dyskinesia: tongue protrusion and vacuous chewing movements frequencies and duration of twitching of the facial musculature. Reserpine-treated rats exhibited a significant increase in the three behavioral parameters of orofacial dyskinesia relative to the saline-treated rats. The co-administration of buspirone in the reserpine-treated rats attenuated the development of orofacial dyskinesia, when compared to the reserpine-treated rats. We also verified that chronic (30 days) buspirone treatment was able to increase apomorphine-induced yawning behavior. The possibility is raised that buspirone attenuates haloperidol-induced increased locomotion and rearing and reserpine-induced orofacial dyskinesia through the development of dopamine autoreceptor supersensitivity. Taken together with previous clinical reports, the present data suggest that buspirone co-administration may lead to important clinical effects concerning different tardive dyskinesia treatment.

Many athletes incorporate high training volumes and limited recovery periods into their training regimes. This may disrupt the fragile balance and the accumulation of exercise stress may exceed an athlete's finite capacity of resistance. A state of elevated fatigue, increased mood disturbance and decreased exercise performance can result. This is commonly known as overreaching and if increased training and limited recovery is continued, it is believed that the more serious state of overtraining may develop. This is relatively commonly experienced in athletes, however little scientific investigation has been conducted to determine the characteristics and underlying mechanisms. The overall aim of this thesis was to gain a greater understanding of the state of overreaching and to specifically provide new information on potential markers of this state as well as possible mechanisms. To study the cumulative effects of exercise stress and subsequent recovery on performance changes, fatigue indicators and possible mechanisms, the training of endurance cyclists was systematically controlled and monitored in two separate investigations. A number of variables were assessed including performance, physiological, biochemical, psychological, immunological and hormonal variables. In addition heart rate variability and serotonergic responsiveness were also assessed. Some of the more pertinent effects of overreaching included an increase in heart rate variability, a reduction in carbohydrate oxidation, an increase in serotonergic responsiveness and a reduction in stress hormone concentrations. These results suggest that autonomic imbalance in combination with decreased hormonal release appears to be related to the decline in performance and elevated fatigue apparent in overreached athletes. Additionally it also appears that alterations in the hypothalamic-pituitary adrenal axis may occur in overreached athletes.

<p>Premenstrual dysphoria, so severe that it affects the lives of the women afflicted, is the condition studied in this thesis. Physiological and pharmacological mechanisms of pathogenetic relevance were investigated. </p><p>Women with premenstrual dysphoria showed a stronger and less dampened response of LH to an estradiol challenge than asymptomatic women, indicating an altered neuroendocrine regulation. In women with premenstrual dysphoria, the LH response was correlated to the severity of irritability and bloating, and the early FSH response was correlated to the severity of depressed mood. </p><p>The positron-emission study showed strong, consistent correlations between worsening of mood symptoms and a decrease in brain trapping of the immediate serotonin precursor, from the mid-follicular to the late luteal phase in women with premenstrual dysphoria. The strongest correlations were seen for the cardinal mood symptoms of premenstrual dysphoria, and for their opposites. Physical symptoms showed weaker or no correlations with the exception of nociceptive symptoms from erogenous body regions which showed positive correlations to serotonin precursor trapping in the right caudate nucleus. The findings are consistent with the serotonin hypothesis of premenstrual dysphoria, and might possibly explain the observed effects of serotonin-augmenting drugs in this condition.</p><p>The partial 5-HT_1A receptor agonist buspirone was superior to placebo in the treatment of premenstrual dysphoria. The weak SRI and 5-HT₂ receptor antagonist nefazodone was not superior to placebo. For women with premenstrual dysphoria in need of medication and who do not tolerate SRIs because of the sexual sideeffects, buspirone may be an alternative drug, since it had no adverse effects on sexual function. </p><p>The prevalence of polycystic ovaries and serum levels of androgens were not higher in women with premenstrual dysphoria than in their asymptomatic counterparts. The findings are not consistent with the hypothesis that irritability in women with premenstrual dysphoria is induced by elevated testosterone levels. </p><p>Thesis results, which are in line with the serotonin hypothesis of premenstrual dysphoria, may imply that increased brain sensitivity is one of the factors underlying severe premenstrual mood symptoms, thereby further supporting a common serotonergic dysregulation in this condition.</p>

Premenstrual dysphoria, so severe that it affects the lives of the women afflicted, is the condition studied in this thesis. Physiological and pharmacological mechanisms of pathogenetic relevance were investigated. Women with premenstrual dysphoria showed a stronger and less dampened response of LH to an estradiol challenge than asymptomatic women, indicating an altered neuroendocrine regulation. In women with premenstrual dysphoria, the LH response was correlated to the severity of irritability and bloating, and the early FSH response was correlated to the severity of depressed mood. The positron-emission study showed strong, consistent correlations between worsening of mood symptoms and a decrease in brain trapping of the immediate serotonin precursor, from the mid-follicular to the late luteal phase in women with premenstrual dysphoria. The strongest correlations were seen for the cardinal mood symptoms of premenstrual dysphoria, and for their opposites. Physical symptoms showed weaker or no correlations with the exception of nociceptive symptoms from erogenous body regions which showed positive correlations to serotonin precursor trapping in the right caudate nucleus. The findings are consistent with the serotonin hypothesis of premenstrual dysphoria, and might possibly explain the observed effects of serotonin-augmenting drugs in this condition. The partial 5-HT1A receptor agonist buspirone was superior to placebo in the treatment of premenstrual dysphoria. The weak SRI and 5-HT2 receptor antagonist nefazodone was not superior to placebo. For women with premenstrual dysphoria in need of medication and who do not tolerate SRIs because of the sexual sideeffects, buspirone may be an alternative drug, since it had no adverse effects on sexual function. The prevalence of polycystic ovaries and serum levels of androgens were not higher in women with premenstrual dysphoria than in their asymptomatic counterparts. The findings are not consistent with the hypothesis that irritability in women with premenstrual dysphoria is induced by elevated testosterone levels. Thesis results, which are in line with the serotonin hypothesis of premenstrual dysphoria, may imply that increased brain sensitivity is one of the factors underlying severe premenstrual mood symptoms, thereby further supporting a common serotonergic dysregulation in this condition.